References
- Borghi C, Dormi A, Veronesi M et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am. Heart J.148, 285–292 (2004).
- Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research group. Arch. Intern. Med.152, 56–64 (1992).
- Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation12, 3384–3390 (2005).
- Nickenig G, Baumer AT, Temur Y et al. Statin-sensitive dysergulated AT1 receptor function and density in hypercolesterolemic men. Circulation100, 2131–2134 (1999).
- Zureik M, Ducimetiere P, Touboul PJ et al. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: longitudinal results from the Aging Vascular Study (EVA) study. Arterioscler. Thromb. Vasc. Biol.20, 1622–1629 (2000).
- Crouse JR, Craven TE, Hagaman AP et al. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid arteries. Circulation92, 1141–1147 (1995).
- Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–152 (2000).
- Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering-drugs: results of prospectively designed overviews of randomised trials. Lancet355, 1955–1964 (2000).
- Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med.348, 383–393 (2003).
- Nickenig G, Jung O, Strehlow K et al. Hypercolesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am. J. Physiol.272, 2701–2707 (1997).
- Wassmann S, Hilgher S, Laufs U et al. Angiotensin II type 1 receptor antagonism improves hypercolesterolemia-associated endothelial disfunction. Arterioscler. Thromb. Vasc. Biol.22, 1208–1212 (2002).
- Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
- Schoenhagen P, Tuzcu EM, Apperson-Hansen C et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation113, 2826–2834 (2006).
- Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
- Davis PH, Dawson JD, Riley WA et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine study. Circulation104, 2815–2819 (2001).